Please login to the form below

Not currently logged in
Email:
Password:

Ariad appoints new CEO

Paris Panayiotopoulos joins the US biotech from EMD Serono

Ariad Paris PanayiotopoulosParis Panayiotopoulos has moved from EMD Serono to join Ariad as its new president and CEO.

Panayiotopoulos succeeds Ariad's founder, chairman and CEO Harvey Berger who is retiring from the Cambridge, US-based biotech company he set up 23 years ago.

Berger will continue at Ariad for a time, serving as a special advisor to its board and new CEO Panayiotopoulos as part of the transition process.

Wayne Wilson, lead director for Ariad, said: “Paris is a dynamic leader with a proven ability to set vision, define strategy, build culture and align teams to successfully execute against objectives.

“He has the necessary skills to bring a renewed focus to company execution as we work together to explore all paths in maximising value for shareholders.”

Prior to his time at EMD Serono, where he was its president, and its parent company Merck KGaA Panayiotopoulos was at Lilly.

Panayiotopoulos said: “I am very pleased to be joining ARIAD at this exciting time. Together with our passionate and highly capable employees, I fully expect that we will maximise the company's commercial potential and further strengthen its pipeline.”

5th January 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics